https://www.selleckchem.com/pr....oducts/l-glutamic-ac
71% and 59.38% (P = 0.041), while the corresponding rates were 69.23% and 70.00%, respectively, for those with and without PIK3CA mutation (P = 0.958). The most frequently reported Grade 3 to 4 adverse events were diarrhea (45.28%), leukopenia (39.62%), and neutropenia (32.08%). No deaths occurred, and no left ventricular ejection fraction 50% or 10 points drop from baseline to before surgery was reported. The addition of pyrotinib to trastuzumab plus chemotherapy is an efficacious and safe regimen for pa
Mi piace
Commento
Condividi
